Lynwood Capital Management’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

Lynwood Capital Management’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,800	Closed	-$108K	–	177
2023 Q1	$108K	Hold	9,800	–	–	0.1%	86
2022 Q4	$1K	Hold	9,800	–	–	﹤0.01%	129
2022 Q3	$1K	Hold	9,800	–	–	﹤0.01%	144
2022 Q2	$1K	Sell	9,800 -3,540	-27%	-$611	﹤0.01%	143
2022 Q1	$3K	Buy	+13,340	New	+$4.01K	﹤0.01%	137

Lynwood Capital Management's IBER.WS Position: Q2 2023 in Review

Lynwood Capital Management sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q2 2023, closing a stake of 9,800 shares — an estimated $108K sold.

Lynwood Capital Management first reported a position in IBER.WS in Q1 2022 and held it in 5 quarters. The position peaked at $108K in Q1 2023. 0 funds tracked by Wall St. Rank hold IBER.WS as of Q2 2023.

Lynwood Capital Management reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q2 2023 after selling out during the quarter.
Lynwood Capital Management sold 9,800 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q2 2023, an estimated $108K.
Lynwood Capital Management first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q1 2022 and held it in 5 quarters.
Lynwood Capital Management's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $108K in Q1 2023.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q2 2023.

Based on Lynwood Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.